Here are four things to know:
1. The implant is composed of a medical grade polymer and does not require fixation to bone or soft tissues. It is designed to mimic the function of the natural meniscus and redistribute loads transmitted across the knee joint.
2. The trials are designed to evaluate the NUsurface Meniscus Implant as a treatment for persistent knee pain caused by injured or deteriorated meniscus tissue.
3. The trials enrolled a combined 243 patients, 176 of which received the NUsurface Meniscus Implant.
4. The trials were conducted in support of Active Implants receiving FDA De Novo 510(k) clearance for the implant.
More articles on surface technology:
16 developments in 3D-printed orthopedic and spine devices in 2018 so far
Cutting Edge Spine receives FDA clearance for PEEK-enhanced cervical interbody system: 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.